胃肠道间质瘤的分子机制与靶向治疗进展

Molecular Mechanisms of Gastrointestinal Stromal Tumors and Advances in Targeted Therapy

摘要: GIST是一种常见的间叶组织肿瘤，好发于胃和小肠，其发生与c-KIT基因和PDGFRA基因突变有关，免疫组化上常有CD117和DOG1表达。其临床没有特异性表现，但可以通过CT和MRI等影像学检查和组织病理学最终确诊。流行病学显示全球范围内GIST的发病率并不高，但随着诊断技术的进步，检出率逐年增加，且该疾病在中老年(60岁左右)人群中更为多发。深入研究GIST的分子机制，许多都涉及了KIT基因或者PDGFRA基因的激活突变，影响其信号通路调控，导致细胞异常增殖，同时细胞微环境的变化在肿瘤发展中起着重要的作用。在靶向治疗领域，伊马替尼等酪氨酸激酶抑制剂治疗在临床上改善GIST患者预后，然而耐药是当下临床难题。研究发现二级耐药的产生，可能与基因突变和肿瘤代谢改变有关。这需要通过开发新药和制定个体化治疗方案来解决。面对靶向治疗带来的挑战，努力克服更多副作用，如何实施组合疗法的耐药，正在成为探索方向。此外，个性化治疗结合新技术的应用也是未来GIST治疗的重要方向之一。随着新的分子标志物的逐渐被发现，医疗研究领域将更加重视个体化治疗，并结合多学科协作，以此达到更好的治疗效果，延长患者的生存期。随着对GIST分子机制的研究和深入，靶向治疗也得以持续地发展。虽然目前仍有待解决的问题，但总体而言，已经改善了患者的治疗效果。在未来，需要继续加强新兴治疗手段的研究，以此解决目前面临的问题，并进一步提高整体治疗预后。

Abstract: GIST is a common mesenchymal tissue tumor that occurs in the stomach and small intestine, and its occurrence is related to mutations in c-KIT gene and PDGFRA gene, and CD117 and DOG1 are often expressed in immunohistochemistry. There are no specific clinical findings, but the diagnosis can be confirmed by imaging tests such as CT and MRI and histopathology. Epidemiology shows that the incidence of GIST worldwide is not high, but with advances in diagnostic technology, the detection rate is increasing year by year, and the disease is more common in middle-aged and older people (around 60 years of age). In-depth study of the molecular mechanism of GIST involves the activation of KIT gene or PDGFRA gene, which affects the regulation of its signaling pathway, leading to abnormal cell proliferation, and changes in the cell microenvironment play an important role in tumor development. In the field of targeted therapy, tyrosine kinase inhibitor therapy such as imatinib has improved the prognosis of GIST patients clinically, but drug resistance is a current clinical problem. Studies have found that the emergence of secondary drug resistance may be related to gene mutations and changes in tumor metabolism. This needs to be addressed through the development of new drugs and the development of individualized treatment regimens. In the face of the challenges brought by targeted therapy, efforts to overcome more side effects, and how to implement drug resistance of combination therapies are becoming the direction of exploration. In addition, the application of personalized treatment combined with new technologies is also one of the important directions of GIST treatment in the future. With the discovery of new molecular markers, the medical research field will pay more attention to individualized treatment and combine multidisciplinary collaboration to achieve better treatment outcomes and prolong patient survival. With the in-depth study of the molecular mechanism of GIST, targeted therapy has also been continuously developed. Although there are still issues to be addressed, overall, patient outcomes have been improved. In the future, it is necessary to continue to strengthen the research of emerging treatment modalities to solve the current problems and further improve the overall treatment prognosis.